Can primaquine therapy for vivax malaria be improved?
Related Experiment Video
Updated: Sep 26, 2026

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
Published on: October 11, 2019
J Kevin Baird1, Karl H Rieckmann
1US Naval Medical Research Unit #2, American Embassy Jakarta, Fleet Post Office, Asia-Pacific 96520-8132, USA. bairdjk@nmaru2.med.navy.mil
Abstract:
The incidence and range of endemic malaria caused by Plasmodium vivax has expanded during the past 30 years. This parasite forms hypnozoites in the liver, creating a persistent reservoir of infection. Primaquine (PQ), introduced 50 years ago, is the only drug available to eliminate hypnozoites. However, lengthy treatment courses and follow-up periods are not conducive to assessing the effectiveness of this drug in preventing relapses. Resistance to standard therapy could be widespread. Studies are urgently needed to gauge this problem and to determine the safety, tolerability and efficacy of shorter courses and higher doses of PQ.
Related Concept Videos
Malaria
Antiprotozoal Agents
Anthelminthic Agents
Pharmaceutical Poisoning: Treatment Strategies
Giardiasis
American Trypanosomiasis

